CTOs on the Move

Pyxis Oncology

www.pyxisoncology.com

 
Founded by Longwood Fund, Pyxis Oncology is building a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers. Pyxis is employing site-specific conjugation technology to develop highly stable ADCs with enhanced therapeutic indexes. Pyxis is also advancing a diverse portfolio of immunotherapies that target broad immune regulators as well as novel immune checkpoints identified through its immuno-oncology and cold tumor discovery efforts.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Stephen Monks
 Chief Technology Officer Profile

Funding

Pyxis Oncology raised $22M on 07/17/2019

Similar Companies

Enzyme by Design

A protein engineering startup passionate about developing safer cancer therapeutics

Tactiva Therapeutics

Tactiva is an immuno-oncology company based in Buffalo, New York, utilizing an innovative, dual T cell receptor (TCR) approach to adoptive T cell therapy.

Palleon Pharmaceuticals

Palleon is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.

Carbon Sciences, Inc

Carbon Sciences Inc. is developing a breakthrough technology to transform carbon dioxide (CO2) emissions into the basic fuel building blocks required to produce gasoline, diesel fuel, jet fuel and other portable fuels.

Ocugen

Ocugen Inc.is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19.